Development of a robust, versatile, and scalable inoculum train for the production of a DNA vaccine

Biotechnology Progress

Volumn 21, Issue 4, 2005, Pages 1038-1047

  Okonkowski, J ^a   Kizer Bentley, L ^a   Listner, K ^a   Robinson, D ^a   Chartrain, M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONCENTRATION (PROCESS); ESCHERICHIA COLI; FERMENTATION; PROCESS CONTROL; RAW MATERIALS; ROBUSTNESS (CONTROL SYSTEMS); VACCINES;

INOCULUM TRAIN; MICROBIAL FERMENTATION PROCESS; PLASMIDS; VIABLE CELLS;

DNA;

DETERGENT; DNA VACCINE; GAG PROTEIN;

ARTICLE; BIOREACTOR; CHEMISTRY; CULTURE MEDIUM; DRUG EFFECT; ESCHERICHIA COLI; FERMENTATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; INSTRUMENTATION; METHODOLOGY; MICROBIOLOGY; PLASMID;

BIOREACTORS; CULTURE MEDIA; DETERGENTS; ESCHERICHIA COLI; FERMENTATION; GENE PRODUCTS, GAG; INDUSTRIAL MICROBIOLOGY; PLASMIDS; VACCINES, DNA;

ESCHERICHIA COLI; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 23344449885     PISSN: 87567938     EISSN: None     Source Type: Journal    
DOI: 10.1021/bp040041p     Document Type: Article

References (28)

1. Babuik, L.; Babiuk, S.; Loehr, B.; van Brunnen Littel-van den Hurk, S. Nucleic acid vaccines: Research tool or commercial reality. Vet. Immunol. Immunopathol. 2000, 76, 1-23.
2. Barouch, D. et al. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vacines by IL-2/lg plasmid administration in rhesus monkeys. Proc. Natl. Acad. Sci. 2000, 97, 4192-4197.
3. Barouch, D. et al. Control of verimia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2001, 290, 486-492.
4. Bergmann-Leitner, E. S.; Leitner, W. W. Danger, death and DNA vaccines. Microbes Infect. 2004, 6 (3), 319-327.
5. Berzofsky, J.; Terabe, M.; Oh, S.; Belyakov, I.; Ahlers, J.; Janik, J.; Morris, J. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J. Clin. Invest. 2004, 113, 1515-1525.
6. Board on Manufacturing and Engineering Design. Theoretical Foundations for Decision Making in Engineering Design; National Academies Press: Washington, DC, 2001.
7. Donnelly, J.; Berry, K.; Ulmer, J. Technical and regulatory hurdles for DNA vaccines. Int. J. Parasitol. 2003, 33, 457-467.
8. Falk, L.; Ball, L. Current status and future trends in vaccine regulation-USA. Vaccine 2001, 19, 1567-1572.
9. FDA. Points to consider in the production and testing of new drugs and biologies produced by recombinant DNA technology. 1985.
10. Ferber, D. Gene therapy: Safer and virus free. Science 2001, 294, 1638-1642.
11. F.I.P. (International Federation of the Pharmaceutial Industries) Committee on Microbial Purity. Validation and environmental monitoring of aseptic processing. J. Parenter. Sci. Technol. 1990, 44, 272-277.
12. Gurunathan, S.; Wu, C.; Friedag, B.; Seder, R. DNA vaccines: a key for inducing long-term cellular immunity. Curr. Opin. Immunol. 2000, 12, 442-447.
13. Gurunathan, S.; Klinman, D.; Seder, R. DNA vaccines: immunology, application, and optimization. Annu. Rev. Immunol. 2000, 18, 927-974.
14. Ignova, M. M.; G. A.; Ward, A. C.; Glassey, J. Fermentation seed quality analysis with self-organising neural networks. Biotechnol. Bioeng. 1999, 64 (1), 82-91.
15. Junker, B.; Seeley, A.; Lester, M.; Kovatch, M.; Schmitt, J.; Oryscwicz, S.; Lynch, J.; Zhang, J.; Greasham, R. Use of frozen aged seed inoculum for secondary metabolite and bioconversion processes at the pilot scale. Biotechnol. Bioeng. 2002, 79, 628-640.
16. Leitner, W.; Thalhamer, J. DNA vaccines for non infectious diseases: new treatments for tumour and allergy. Expert Opin. Biol. Ther. 2003, 3, 627-638.
17. Leitner, W.; Ying, H.; Restifo, N. DNA and RNA-based vaccines: principles, progress and prospects. Vaccine 2000, 18, 765-777.
18. Martinkova, L. M., F.; Ujcova, E.; Kolin, F.; Zajicek, J. Effect of Age, Amount of Inoculum and Inoculation Medium Composition on Lactic Acid Production from Glucose by Lactobacillus casei subsp. rhamnosus. Folia Microbiol. 1991, 36 (3), 246-248.
19. Meredith, J.; Mantel, S., Jr. Project Management: A Managerial Approach. John Wiley & Sons: New York, 2003.
20. Monod, J. The growth of bacterial cultures. Annu. Rev. Microbiol. 1949, 3, 371-394.
21. Mountain, A. Gene therapy: the first decade. TIBTECH 2000, 18, 119-128.
22. Patnaik, P. R. Start-up sensitivity to the initial state of a batch bioreactor for a recombinant Escherichia coli in a complex medium. Bioprocess Eng. 1996, 15, 215-219.
23. PDA. Fundamentals of an environmental monitoring program. PDA J. Pharm. Sci. Technol. 2001, 55, 1-35.
24. Pirt, J. S. Growth lag. Principles of Microbe and Cell Cultivation; Blackwell Scientific: Oxford, U.K., 1975; pp 194-198.
25. Powell, K. DNA vaccines-back in the saddle again? Nat. Biotechnol. 2004, 22, 799-801.
26. Prather-Jones, K.; Sagar, S.; Murphy, J.; Chartrain, M. Industrial scale production of plasmid DNA for vaccine and gene therapy: plasmid design, production, and purification. Enzyme Microb. Technol. 2003, 33 (7), 865-883.
27. Shroff, K.; Smith, L.; Baine, Y.; Higgins, T. Potential for plasmid DNAs as vaccines for the new millenium. Pharm. Sci. Technol. Today 1999, 2, 205-212.
28. Warr, S.; Gershater, C.; Box, S. Seed stage development for improved fermentation performance: increased milbemycin production by Streptomyces hygroscopicus. J. Ind. Microbiol. 1996, 16, 295-300.